Adicet Bio to Present at Upcoming Investor Conferences
08/01/2022 - 04:10 PM
REDWOOD CITY, Calif. & BOSTON --(BUSINESS WIRE)--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.
Details of the events are as follows:
BTIG Biotech Conference , August 8-9, 2022
Chen Schor , President & CEO, will participate in a fireside chat at the conference on Monday, August 8, 2022 .
Wedbush Pacgrow Healthcare Conference , August 9-10, 2022
Chen Schor , President & CEO, will participate in a virtual panel discussion titled, “A View to a Kill(er) Cell – Part 1” on Wednesday, August 10, 2022 , at 1:10 P.M. ET .
Canaccord Genuity Annual Growth Conference, August 8-11, 2022 , Boston, Massachusetts
Chen Schor , President & CEO, will present a corporate overview on Thursday, August 11, 2022 , at 11:00 A.M. ET .
The live audio webcast of the Canaccord Genuity presentation and Wedbush panel can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com . An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220801005661/en/
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
janhavi.mohite@sternir.com
Source: Adicet Bio, Inc.
ACET Rankings
#5484 Ranked by Stock Gains
ACET Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Distribution Services, Medical Distributors, Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Boston
About ACET
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
